SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Higuchi Ichiyō

PatientHiguchi Ichiyō
Date of birth2002-05-02
IdentifiersMRN HR-NI029-SYN; SSN (made up) 000-29-5108
Document date2026-05-01
AuthorAiko Lindgren-Tanaka, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review on tuberculosis treatment. [S]

History of Present Illness

Ms. Higuchi returns two weeks into treatment. She has taken all fourteen doses on daily video calls with the public health center nurse. The evening fevers stopped about ten days in, the night sweats are lighter, and the cough is less frequent and dry. She had mild nausea after the morning doses in the first week, which went once she moved them to bedtime with a small snack. Her urine and tears are orange, as expected. She has no yellowing, dark urine, abdominal pain, rash, numbness, or change in vision or colors. The liquid culture from her first sputum specimen grew Mycobacterium tuberculosis complex after twelve days. She is eating three meals and two snacks a day with the supplement drinks. The public funding was approved. She has begun to write again for about an hour each morning. [S]

ElementDetail
TreatmentFourteen of fourteen doses observed by video
SymptomsNo fever for four days; lighter night sweats; less cough
Side effectsMild nausea in the first week, gone with bedtime dosing; orange urine and tears
CultureMycobacterium tuberculosis complex grown from the first specimen

Review of Systems

SystemResultFinding
RespiratoryPositiveOccasional dry cough; no blood; less breathless
ConstitutionalPositiveLighter night sweats; no fever for four days; appetite better
GastrointestinalNegativeNo nausea now; no vomiting, abdominal pain or jaundice
EyesNegativeNo blurred vision or change in colors
NeurologicalNegativeNo numbness or tingling

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Isoniazid 100 mg tablets, two tablets (200 mg) daily200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeksOral route2026-04-17 to 2026-10-15completedS
Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeksOral route2026-04-17 to 2026-10-15completedS
Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phaseOral route2026-04-17 to 2026-06-11completedS
Ethambutol 100 mg tablets, six tablets (600 mg) daily600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results returnOral route2026-04-17 to 2026-05-22stoppedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route2026-04-17 to 2026-10-15completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-05-01Body height148cmS
2026-05-01Body weight39.2kgS
2026-05-01Body mass index (BMI) [Ratio]17.9kg/m2S
2026-05-01Systolic blood pressure100mm[Hg]S
2026-05-01Diastolic blood pressure62mm[Hg]S
2026-05-01Heart rate90/minS
2026-05-01Respiratory rate18/minS
2026-05-01Body temperature37.1CelS
2026-05-01Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-05-01Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
2026-05-01Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L10-35 U/LNormalS
2026-05-01Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-05-01Visual acuity uncorrected Right eye by ETDRS eye chart85{letters}>=80NormalS
2026-05-01Visual acuity uncorrected Left eye by ETDRS eye chart84{letters}>=80NormalS

Physical Exam

Vital signs recorded on 2026-05-01; see the Vital Signs section. [S]

SystemFinding
GeneralLess tired; weight 39.2 kg, up 0.7 kg; temperature 37.1 °C, pulse 90
EyesNo icterus. Visual acuity 85 letters on the right and 84 on the left; Ishihara plates read correctly with each eye
RespiratoryA few fine crackles over the right upper zone, fewer than at diagnosis
AbdomenSoft and non-tender; liver not enlarged
NeurologicalNormal sensation and reflexes in the feet

Problems

ProblemClinical statusVerificationCodeProvenance
Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and cultureresolvedconfirmed R05.3S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D).
Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected)activeconfirmed A15.0S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic.
Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dLactiveconfirmed E44.0S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty.
Low and irregular income from writing, with a household to support; costs of care are a barrieractiveconfirmed Z59.6S — Synthetic social need anchored to her documented poverty and household responsibilities.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationSymptom review: cough, sputum, fever, night sweatsAt least monthly during treatmentCompleted todayNo fever for four days; lighter night sweats; occasional dry cough
Self-managementWeight and nutritionEvery visit; dose review if weight changes by more than about 5 kgCompleted today39.2 kg, up 0.7 kg; doses unchanged
Medication safetyHepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine)Every visit and every observed doseCompleted todayMild nausea in the first week only; no jaundice, dark urine or pain
LaboratoryLiver tests (ALT, AST, bilirubin)Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptomsCompleted todayALT 22, AST 24 U/L, bilirubin 0.6 mg/dL, all normal
ImagingVisual acuity and color visionBaseline and monthly while on ethambutolCompleted today85 letters on the right and 84 on the left; color vision normal
LaboratorySputum smear and cultureAt diagnosis, at two weeks, and at the end of the intensive phase (two months)Completed todayLiquid culture of the first specimen grew Mycobacterium tuberculosis complex at twelve days; two-week specimen sent today
LaboratoryDrug susceptibility testing of the first isolateOnce, on the first positive cultureOrderedSet up on the isolate; result expected in about three weeks
Medication safetyDoses observed and missed (video-observed therapy)Every visitCompleted todayFourteen of fourteen doses observed
Medication safetyPeripheral neuropathy check, with pyridoxineEvery visitCompleted todayNo neuropathy; pyridoxine 50 mg daily
Medication safetyRifampin drug-interaction review, including hormonal contraceptionWith every new medicineCompleted todayNo new medicines
Self-managementHome precautions and the criteria for releaseUntil two weeks of treatment with clinical improvement, for smear-negative diseaseCompleted todayReleased from home precautions today with the public health center's agreement
ReferralContact investigation (household and close contacts)Led by the public health center, from diagnosisReferredUnder way with the public health center; results not part of her record
ReferralPublic funding and other help with costsAt diagnosis and as neededCompleted todayPublic funding approved
SurveyDepression screen (PHQ-9)At diagnosis, at two months, and at the end of treatmentUp to datePHQ-9 8 at intake; next at two months

Goal progress:

Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022); Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); 結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law (current); 結核医療費の公費負担 (Public funding of tuberculosis medical costs under Articles 37 and 37-2 of the Infectious Diseases Control Law) (current); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012)

Follow-up: Ethambutol stopped by phone when susceptibility results return. Monthly liver tests. End-of-intensive-phase review at eight weeks with the two-month sputum. Call the same day for hepatitis symptoms or any change in vision. Next scheduled visit 2026-06-12: end of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phase. [S]